HEL13.1, ALS50
UHi002-A
General
Cell Line |
|
hPSCreg name | UHi002-A |
Cite as: | UHi002-A (RRID:CVCL_RL11) |
Alternative name(s) |
HEL13.1, ALS50
|
Cell line type | Human induced pluripotent stem cell (hiPSC) |
Similar lines |
UCLi004-A (RCi173, RCFB60c6) Donor's gene variants: C9orf72, C9orf72 Donor diseases: Amyotrophic lateral sclerosis Frontotemporal dementia UCLi004-B (RCFB60c7, RCi177) Donor's gene variants: C9orf72, C9orf72 Donor diseases: Amyotrophic lateral sclerosis Frontotemporal dementia UCLi004-C (RCi172, RCFB60c2) Donor's gene variants: C9orf72, C9orf72 Donor diseases: Amyotrophic lateral sclerosis Frontotemporal dementia PFIZi013-A (RCi215, RCFB59 C9) Donor's gene variants: TARDBP, TARDBP Donor diseases: Amyotrophic lateral sclerosis SAPi004-A (ALS III, TDP43-A382T/A382T, ALS III-TDP43-A382T/A382T) Donor diseases: Amyotrophic lateral sclerosis |
Last update | 14th May 2022 |
Notes | Derived at Biomedicum Stem Cell Center, University of Helsinki, Finland. |
User feedback | |
Provider |
|
Generator | University of Helsinki (UH) |
Derivation country | Finland |
External Databases |
|
BioSamples | SAMEA5236073 |
Cellosaurus | CVCL_RL11 |
Wikidata | Q54749292 |
General Information |
|
Publications | |
* Is the cell line readily obtainable for third parties? |
No |
Donor Information
General Donor Information |
|
Sex | male |
Phenotype and Disease related information (Donor) |
|
Diseases | A disease was diagnosed.
|
External Databases (Donor) |
|
BioSamples | SAMEA5236092 |
Ethics
Has informed consent been obtained from the donor of the embryo/tissue from which the pluripotent stem cells have been derived? | Yes |
Was the consent voluntarily given? | Yes |
Has the donor been informed that participation will not directly influence their personal treatment? | Yes |
Can you provide us with a copy of the Donor Information Sheet provided to the donor? | No |
Please provide contact information of the holder of the original Donor Information Sheet. | Prof. Pentti Tienari, Helsinki University hospital (pentti.tienari@hus.fi) |
Do you (Depositor/Provider) hold the original Donor Consent Form? | No |
If you do not hold the Donor Consent Form, do you know who does? | Yes |
Please provide the contact information | Prof. Pentti Tienari, Helsinki University hospital (pentti.tienari@hus.fi) |
Please indicate whether the data associated with the donated material has been pseudonymised or anonymised. | pseudonymised |
Does consent explicitly allow the derivation of pluripotent stem cells? | Yes |
Does consent expressly prevent the derivation of pluripotent stem cells? | No |
Does consent prevent CELLS DERIVED FROM THE DONATED BIOSAMPLE from being made available to researchers anywhere in the world? | No |
How may genetic information associated with the cell line be accessed? | Controlled Access |
Will the donor expect to receive financial benefit, beyond reasonable expenses, in return for donating the biosample? | No |
Has a favourable opinion been obtained from a research ethics committee, or other ethics review panel, in relation to the Research Protocol including the consent provisions? | Yes |
Name of accrediting authority involved? | Ethics Committee of Helsinki and Uusimaa Hospital District |
Approval number | Dnro 106/2010 |
For generation of the cell line, who was the supplier of any recombined DNA vectors or commercial kits used? |
hIPSC Derivation
General |
|
Source cell type |
A connective tissue cell which secretes an extracellular matrix rich in collagen and other macromolecules. Flattened and irregular in outline with branching processes; appear fusiform or spindle-shaped.; These cells may be vimentin-positive, fibronectin-positive, fsp1-positive, MMP-1-positive, collagen I-positive, collagen III-positive, and alpha-SMA-negative.
|
Source cell origin |
Any portion of the organ that covers that body and consists of a layer of epidermis and a layer of dermis.
Synonyms
|
Reprogramming method |
|
Vector type | Integrating |
Vector | Virus (Retrovirus) |
Genes | |
Is the used vector excisable? |
Unknown |
Absence of reprogramming vector(s)? |
Unknown |
Reprogramming vectors silenced? | |
Vector free reprogramming |
|
Other |
|
Derived under xeno-free conditions |
Unknown |
Derived under GMP? |
Unknown |
Available as clinical grade? |
Unknown |
Culture Conditions
Medium |
Essential 8™
|
Characterisation
Analysis of Undifferentiated Cells
Marker | Expressed | Immunostaining | RT-PCR | Flow Cytometry | Enzymatic Assay | Expression Profiles |
TRA 1-60 |
Yes |
|
||||
NANOG |
Yes |
|
||||
POU5F1 (OCT-4) |
Yes |
|
||||
SSEA-3 |
Yes |
|
Differentiation Potency
Genotyping
Karyotyping (Cell Line) |
|
Has the cell line karyotype been analysed? |
No
|
Other Genotyping (Cell Line) |
Login to share your feedback, experiences or results with the research community.